A detailed history of Sandy Spring Bank transactions in Cassava Sciences Inc stock. As of the latest transaction made, Sandy Spring Bank holds 1,050 shares of SAVA stock, worth $2,467. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,050
Previous 1,050 -0.0%
Holding current value
$2,467
Previous $12,000 150.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$18.44 - $26.41 $18,440 - $26,410
1,000 Added 2000.0%
1,050 $21,000
Q1 2022

May 03, 2022

BUY
$32.6 - $53.05 $1,630 - $2,652
50 New
50 $2,000
Q4 2021

Feb 11, 2022

SELL
$36.77 - $90.91 $18,385 - $45,455
-500 Closed
0 $0
Q3 2021

Nov 05, 2021

BUY
$41.79 - $135.3 $20,895 - $67,650
500 New
500 $31,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $94.2M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Sandy Spring Bank Portfolio

Follow Sandy Spring Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.